Previous Close | 1.4600 |
Open | 1.4400 |
Bid | 1.4500 x 1100 |
Ask | 1.4700 x 2200 |
Day's Range | 1.4200 - 1.4727 |
52 Week Range | 1.1800 - 3.9900 |
Volume | |
Avg. Volume | 300,006 |
Market Cap | 55.362M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.6360 |
Earnings Date | Nov 10, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BOLT
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer
– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022– BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022– Cash balance of $209.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results